ALNYLAM PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wells Fargo maintained an 'Equal-Weight' rating on Alnylam Pharmaceuticals (ALNY) but lowered its price target to $253. The stock is trading at $225.59, which GuruFocus estimates as 58.8% undervalued. Insider selling and mixed analyst sentiment reflect cautious market views.
Truist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.
The Scottish Medicines Consortium approved vutrisiran for adults with ATTR-CM, enabling access via NHS Scotland. Developed by Alnylam, vutrisiran is a long-acting treatment targeting the underlying biology of the condition. Around 1,800 people in Scotland may be affected. The therapy is also indicated for hereditary ATTR amyloidosis. The decision follows a similar recommendation by NICE in England and Wales.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ALNY (ALNYLAM PHARMACEUTICALS, INC.). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.
Recent ALNY coverage spans financial news, market movers and technology.
In the last 30 days, ALNY insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($399K). The most active reporter was SUPRAN BRYAN, EVP, CLO and Secretary, with 1 filing.
Analyst price‑target cut suggests modest downside pressure.
Inclusion in a preview without additional company-specific facts provides minimal incremental trading information.
SMC acceptance expands reimbursed access in Scotland, supporting vutrisiran uptake and de-risking regional commercialization.
Insider sale by a senior executive may signal personal concerns about the stock.
Analyst sentiment is positive, but no new catalyst is disclosed.
AlphAI scores every news story that mentions ALNY with an AI model for sentiment and relevance, and aggregates insider trades from ALNYLAM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo maintained an 'Equal-Weight' rating on Alnylam Pharmaceuticals (ALNY) but lowered its price target to $253. The stock is trading at $225.59, which GuruFocus estimates as 58.8% undervalued. Insider selling and mixed analyst sentiment reflect cautious market views.
2 min readTruist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.
7 min readThe Scottish Medicines Consortium approved vutrisiran for adults with ATTR-CM, enabling access via NHS Scotland. Developed by Alnylam, vutrisiran is a long-acting treatment targeting the underlying biology of the condition. Around 1,800 people in Scotland may be affected. The therapy is also indicated for hereditary ATTR amyloidosis. The decision follows a similar recommendation by NICE in England and Wales.
3 min readSUPRAN BRYAN (EVP, CLO and Secretary) sold 1,758 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $226.88 ($0.40M total) on 2026-10-02.
1 min readAlnylam Pharmaceuticals (ALNY) stock fell 40% from its peak in 2026, but 22 of 29 analysts rate it 'buy' or 'strong buy' with a 50% upside. Revenue grew 72% YoY in Q2, and analysts see long-term potential despite guidance cuts. Pfizer's (PFE) patent and AstraZeneca's (AZN) setback may benefit Alnylam's pipeline.
3 min readAlnylam Pharmaceuticals (ALNY) stock rose 8.51% on positive RNAi pipeline updates and analyst upgrades. Analysts set price targets ranging from $318 to $455, citing strong clinical data and growth prospects. The company reported $3.71B in trailing revenue, a 92.1% gross margin, and positive EBIT margin of 23.4%.
3 min readAlnylam Pharmaceuticals (ALNY) rose 3.4% on September 2, 2026, driven by investor reaction to its late-August ESC Congress data update, which highlighted positive subgroup and pooled analyses for vutrisiran and zilebesiran. The company also announced upcoming investor conference webcasts. No major regulatory filings were tied to the gain.
1 min readAstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) discontinued a phase 3 trial for Wainua, a combination therapy for ATTR-CM. Analysts debate whether Alnylam Pharmaceuticals (ALNY) can succeed with its RNA silencing drugs in this area. ALNY's drugs are being considered for use with standard TTR stabilizers, targeting the disease through different pathways. The outcome may impact the ATTR-CM market and RNA therapeutics sector.
2 min readAnalysts at Jefferies, Evercore ISI, and BMO Capital maintained Buy ratings on Ascendis Pharma (ASND), Alnylam Pharma (ALNY), and Crispr Therapeutics (CRSP), with price targets of $330, $325.20, and $76 respectively. The consensus ratings are Strong Buy for ASND and ALNY, and Moderate Buy for CRSP, with average price targets indicating potential upside.
2 min readAlnylam Pharmaceuticals shared data supporting Amvuttra's use in various transthyretin amyloidosis patients, including those on Pfizer's tafamidis. The company also reported positive subgroup results for its experimental drug zilebesiran.
2 min read
